Showing 261-270 of 381 results for "".
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- Lumenis Introduces NuEra Tighthttps://practicaldermatology.com/news/lumenis-introduces-nuera-tight/2460502/Lumenis is rolling out the NuEra Tight with FocalRF technology for body contouring. NuEra Tight will be available worldwide starting with the United States in August 2020 and Europe, the Middle East and Asia later this year. "Radio Frequency treatments are among the most
- Early Study Demonstrates Roflumilast cream Safe and Effective for Chronic Plaque Psoriasishttps://practicaldermatology.com/news/early-study-demonstrates-roflumilast-cream-safe-and-effective-for-chronic-plaque-psoriasis/2460493/Arcutis Biotherapeutics, Inc. shared positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis that were published in the August issue of the Journal of Drugs in Dermatology. The results demonstrate that ARQ-151 (r
- Researchers Explore Nitric Oxide to Slow Progression of COVID-19https://practicaldermatology.com/news/industry-responds-to-covid-19-researchers-call-for-exploration-of-nitric-oxide-to-slow-progression-of-covid-19/2460477/George Washington University (GW) researchers urge renewed research of nitric oxide treatment as a potential tool to fight SARS-CoV-2, the coronavirus that causes COVID-19, in a review published in the journal Nitric Oxide. The authors suggest that if nitric oxide's efficacy is illustrat
- Regenerative Medicine Business News: Bimini Acquires Healeonhttps://practicaldermatology.com/news/regenerative-medicine-business-news-bimini-acquires-healeon/2460432/Bimini Health Tech has acquired Healeon Medical, Inc., a company that designs, develops, manufactures, and markets medical devices for autologous, point-of-care treatments. Healeon's products include: the signature HD PRP system which fe
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- Done Deal: AbbVie Completes Acquisition of Allerganhttps://practicaldermatology.com/news/done-deal-abbvie-completes-acquisition-of-allergan/2460389/AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elec
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugshttps://practicaldermatology.com/news/covid-19-update-aad-others-react-to-potential-shortage-of-malaria-and-arthritis-drugs-1/2460320/The American Academy of Dermatology along with the Lupus Foundation of America, the American College of Rheumatology, and the Arthritis Foundation are concerned about hydroxychloroquine and chloroquine shortages and how it will impact patients with autoimmune diseases. The groups sent a